Fig. 8

The schematic results of this study. Abeta-42, amyloid beta peptide 42; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ALSmd, ALS mimic disorders; Con, all non-ALS controls; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; HCs, healthy controls; MND, motor neuron disease; NCs, neurodegenerative controls; NFH, neurofilament heavy chain; NfL, neurofilament light chain; NNCs, non-neurodegenerative controls; p-tau, phosphorylated tau; t-tau, total tau